Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 134

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Comprehensive Review of Current and Upcoming Anti-Obesity Drugs

Son, Jang Won, Kim, Sungrae · 2020 · Diabetes & Metabolism Journal

Abstract

Obesity is among the leading causes of morbidity and mortality worldwide and its prevalence continues to increase globally. Because obesity is a chronic, complex, and heterogeneous disease influenced by genetic, developmental, biological, and environmental factors, it is necessary to approach obesity with an integrated and comprehensive treatment strategy. As it is difficult to achieve and sustain successful long-term weight loss in most patients with obesity through lifestyle modifications (e.g., diet, exercise, and behavioral therapy), pharmacological approaches to the treatment of obesity should be considered as an adjunct therapy. Currently, four drugs (orlistat, naltrexone extended-release [ER]/bupropion ER, phentermine/topiramate controlled-release, and liraglutide) can be used long-term (>12 weeks) to promote weight loss by suppressing appetite or decreasing fat absorption. Pharmacotherapy for obesity should be conducted according to a proper assessment of the clinical evidence and customized to individual patients considering the characteristics of each drug and comorbidities associated with obesity. In this review, we discuss the mechanisms of action, efficacy, and safety of these available long-term anti-obesity drugs and introduce other potential agents under investigation. Furthermore, we discuss the need for research on personalized obesity medicine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4093/dmj.2020.0258

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 40

  1. 10.1016/s0140-6736(05)67483-1 · DOI · Paper page
  2. 10.2337/db08-0210 · DOI · Paper page
  3. 2000, WHO Consultation on Obesity
  4. 10.1016/S0140-6736(18)32822-8 · DOI · Paper page
  5. 10.1038/nrendo.2017.122 · DOI · Paper page
  6. 10.2165/00003495-199958040-00015 · DOI
  7. 10.1592/phco.20.4.270.34882 · DOI · Paper page
  8. Drew, 2007, Obesity management: update on orlistat, 817
  9. 10.1136/bmj.39406.519132.ad · DOI
  10. 10.1016/s0014-2999(02)01422-x · DOI · Paper page
  11. 10.1001/jama.293.23.2873 · DOI · Paper page
  12. 10.2147/dddt.s55587 · DOI · Paper page
  13. 10.1038/nature14260 · DOI · Paper page
  14. Dutia, 2012, β-Endorphin antagonizes the effects of α-MSH on food intake and body weight, 4246
  15. 10.1007/s40265-015-0427-5 · DOI
  16. 10.1016/s0140-6736(10)60888-4 · DOI · Paper page
  17. Apovian, 2013, A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II), 935
  18. 10.1038/oby.2010.147 · DOI · Paper page
  19. 10.1007/978-3-642-24716-3_20 · DOI
  20. 10.1038/oby.2011.330 · DOI · Paper page
  21. 10.1001/jama.2016.7602 · DOI · Paper page
  22. 10.1002/pds.3612 · DOI
  23. 10.1016/j.yend.2012.05.008 · DOI
  24. 10.1111/j.1467-789X.2011.00860.x · DOI
  25. 10.1038/nrendo.2011.77 · DOI · Paper page
  26. 10.1016/S0140-6736(17)30069-7 · DOI · Paper page
  27. 10.1016/S0140-6736(15)00803-X · DOI · Paper page
  28. 10.1016/j.rbmo.2017.03.023 · DOI · Paper page
  29. 10.1016/s2213-8587(19)30157-3 · DOI · Paper page
  30. 10.1056/nejmc1611289 · DOI · Paper page
  31. 10.2337/dc15-0772 · DOI · Paper page
  32. Wang, 2014, Effect of combined naltrexone and bupropion therapy on the brain’s reactivity to food cues, 682
  33. 10.4158/ep161356.esgl · DOI · Paper page
  34. 10.1038/clpt.2013.204 · DOI · Paper page
  35. 10.1007/s00018-014-1650-z · DOI
  36. 10.1038/s41591-018-0015-9 · DOI · Paper page
  37. Haws, 2020, Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome, 2133
  38. 10.1016/s0140-6736(08)61525-1 · DOI · Paper page
  39. 10.1038/ijo.2010.87 · DOI
  40. 10.1007/s00592-017-0994-x · DOI

Cited by

See all 134

Metadata

Authors
Son, J. W., & Kim, S.
Venue
Diabetes & Metabolism Journal
Published
2020-12-31
Volume
44
Issue
6
Pages
802-818
ISSN
  • 2233-6079
  • 2233-6087
Cited by
134
References
33
Language
en
Licence
creativecommons.org/licenses/by-nc/4.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.